Rucaparib is a targeted therapy drug mainly used in patients with recurrent ovarian cancer and metastatic castration-resistant prostate cancer who carry BRCA gene mutations. This article will comprehensively analyze the key information of this drug from the three core perspectives of drug instructions, medical insurance and price, efficacy and side effects, and help patients and their families better understand its clinical application and economic burden.

Rucaparib instruction manual

Rucaparib was developed by Clovis Oncology in the United States and approved by the FDA in 2016. The drug is a PARP inhibitor that works by blocking the DNA repair mechanism of tumor cells and is suitable for the maintenance treatment of patients with specific gene mutations.

Basic information about the drug

The active ingredient of Rubraca is Rucaparib in tablet form and is available in 200mg, 250mg and 300mg sizes. The appearance of the tablets varies depending on the dose, for example, the 300mg tablets are yellow oval in shape and are engraved with the "C3" logo. The drug should be stored in a dark seal to avoid high temperature or humidity environment, and the expiration date is 24 months.

Dosing and dose adjustment

The recommended dose is 600 mg orally twice daily (two tablets of 300 mg) for a total dose of 1200 mg, either before or after meals. If the patient misses or vomits, there is no need to make up the dose, and the medication needs to be continued as planned. Liver and kidney function should be monitored regularly during treatment, and the dose should be adjusted according to adverse effects, such as when bone marrow suppression occurs, and the dose can be suspended or reduced.

The standard use of Rucaparib should be strictly adhered, especially when it comes to dose adjustment and management of drug interactions. Patients should be alert to the risk of concomitant use with other CYP enzyme substrate drugs, and adjust the dose of concomitant drugs if necessary.

Health insurance and prices in Rucaparib

At present, Rucaparib has not been approved for marketing in Chinese mainland and has not been included in the medical insurance catalog, and patients need to obtain it through cross-border channels, which has a high financial burden.

Generic drugs vs. price differences

The price of generic drugs produced by BDR pharmaceutical factories in India is relatively low. The price of the original drug (Rucaparib version) 300mg specification is high and the price difference is obvious. When choosing generic drugs, patients need to pay attention to distinguishing the authenticity and avoid buying expired or inferior drugs.

Drug purchase channels and risk warnings

Purchasing drugs through formal medical institutions or cross-border e-commerce platforms is the main way, but it is necessary to verify the production date, packaging integrity and supplier qualifications of the drugs. Although some generic drugs are inexpensive, they lack strict supervision, and there are uncertainties and safety hazards in efficacy.

Price differentials and lack of health insurance pose a dual challenge for patients. On the premise of clarifying the quality of drugs, the key to controlling the cost of treatment is to reasonably choose the purchase channels of drugs.

Efficacy and side effects of Rucaparib

As a targeted drug for BRCA mutation-related cancers, Rucaparib has obvious performance in prolonging progression-free survival, but it also comes with a certain risk of adverse reactions.

Indications and mechanism of action

Rucaparib mainly targets PARP1, PARP2 and PARP3 enzymes to inhibit the DNA damage repair ability of tumor cells. Clinical data showed that the median progression-free survival of ovarian cancer patients was extended to 10.8 months, and the overall response rate of prostate cancer patients was about 44%.

Adverse effects and management

Common adverse reactions include nausea, fatigue, anemia, and abnor mal liver function, with an incidence of more than 10%. Serious risks such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) require focused surveillance. Patients with persistent vomiting or abnormal blood counts should seek medical attention to adjust their treatment regimen.

The balance between efficacy and side effects is the core consideration of Rucaparib in clinical application. With regular monitoring and individualized dose management, the benefits of treatment can be maximized and potential risks can be minimized.